Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIPL up-regulation (original) (raw)

References

1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Rauch C, Smith CA . Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–682.
   Article CAS PubMed Google Scholar
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A . Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687–12690.
   Article CAS PubMed Google Scholar
3. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH . Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163.
   Article CAS PubMed Google Scholar
4. Ashkenazi A, Pai RC, Fong S, Lueng S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH . Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162.
   Article CAS PubMed PubMed Central Google Scholar
5. Griffith TS, Lynch DH . TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 254: 439–459.
   Google Scholar
6. De Maria R, Zeuner A, Eramo A, Domenichelli C, Bonci D, Grignani F, Srinivasula SM, Alnemri ES, Testa U, Peschle C . Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 1999; 401: 489–493.
   Article CAS PubMed Google Scholar
7. Song K, Chen Y, Goke R, Wilmen A, Seidel C, Goke A, Hilliard B, Chen Y . Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000; 191: 1095–1103.
   Article CAS PubMed PubMed Central Google Scholar
8. Jo M, Kim T-H, Seol D-W, Esplen JE, Dorko K, Billiar TR, Strom SC . Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564–567.
   Article CAS PubMed Google Scholar
9. Schulze-Osheroff K, Ferrari D, Los M, Wesselborg S, Peter ME . Apoptosis signaling by death receptors. Apoptosis signaling by death receptors. Eur J Biochem 1998; 254: 439–459.
   Article Google Scholar
10. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P . Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000; 482: 193–199.
    Article CAS PubMed Google Scholar
11. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP . Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002; 99: 2162–2171.
    Article CAS PubMed Google Scholar
12. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwekorie C, Onwudiwe N, Srivastava RK . Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001; 20: 6073–6083.
    Article CAS PubMed Google Scholar
13. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowsli P, Ashkenazi A . Control of TRAIL-induced apoptosis by a family of signalling and decoy receptors. Science 1997; 277: 818–821.
    Article CAS PubMed Google Scholar
14. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A . A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7: 1003–1006.
    Article CAS PubMed Google Scholar
15. Chan TO, Rittenhouse SE, Tsichlis PN . AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999; 68: 965–1014.
    Article CAS PubMed Google Scholar
16. Brazil DP, Hemmings BA . Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001; 26: 657–664.
    Article CAS PubMed Google Scholar
17. Nicholson KM, Anderson NG . The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381–395.
    Article CAS PubMed Google Scholar
18. Cantrell DA . Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001; 114: 1439–1445.
    CAS PubMed Google Scholar
19. Lawlor MA, Alessi DR . PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J Cell Sci 2001; 114: 2903–2910.
    CAS PubMed Google Scholar
20. Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandy SK, Nwokorie C, Onwudiwe N, Svrivastava RK . Pro-survival function of Akt/protein kinase B in prostate cancer cells: relationship with TRAIL resistance. J Biol Chem 2001; 276: 38361–38369.
    Article CAS PubMed Google Scholar
21. Beresford SA, Davies MA, Gallick GE, Donato NJ . Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells. J Interfer Cytokine Res 2001; 21: 313–322.
    Article CAS Google Scholar
22. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C . A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271–279.
    Article CAS PubMed Google Scholar
23. Curti A, Ratta M, Corinti S, Girolomoni G, Ricci F, Tazzari P, Siena M, Grande A, Fogli M, Tura S, Lemoli RM . Interleukin-11 induces Th2 polarization of human CD4(+) T cells. Blood 2001; 97: 2758–2763.
    Article CAS PubMed Google Scholar
24. Borgatti P, Martelli AM, Bellacosa A, Casto R, Massari L, Capitani S, Neri LM . Translocation of Akt/PKB to the nucleus of osteoblast-like MC3T3-E1 cells exposed to proliferative growth factors. FEBS Lett 2000; 477: 27–32.
    Article CAS PubMed Google Scholar
25. Martelli AM, Bortul R, Bareggi R, Grill V, Narducci P, Zweyer M . Biochemical and morphological changes in the nuclear matrix prepared from apoptotic HL-60 cells. Effect of different stabilizing procedures. J Cell Biochem 1999; 74: 99–110.
    Article CAS PubMed Google Scholar
26. Martelli AM, Bortul R, Bareggi R, Tabellini G, Grill V, Baldini G, Narducci P . The pro-apoptotic drug camptothecin stimulates phospholipase D activity and diacylglycerol production in the nucleus of HL-60 human promyelocytic leukemia cells. Cancer Res 1999; 59: 3961–3967.
    CAS PubMed Google Scholar
27. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC . TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma : therapeutic applications. Blood 2001; 98: 795–804.
    Article CAS PubMed Google Scholar
28. Lamothe B, Aggarwal BB . Ectopic expression of Bcl-2 and Bcl-XL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukaemia cell line HL-60. J Interfer Cytokine Res 2002; 22: 269–279.
    Article CAS Google Scholar
29. Cuvillier O, Levade T . Sphingosine 1-phosphate antagonizes apoptosis of human leukaemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood 2001; 98: 2828–2836.
    Article CAS PubMed Google Scholar
30. Leslie NR, Downes CP . PTEN: the down side of PI 3-kinase signalling. Cell Signal 2002; 14: 285–295.
    Article CAS PubMed Google Scholar
31. Wen J, Ramadevi N, Nguyen D, Perkins CM, Worthington E, Bhalla K . Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukaemia cells. Blood 2000; 96: 3900–3906.
    CAS PubMed Google Scholar
32. Panka Dj, Mano T, Suhara T, Walsh K, Mier JW . Phosphatidylinositol 3-kinase/Akt activity up-regulates cFLIP expression in tumor cells. J Biol Chem 2001; 276: 6893–6896.
    Article CAS PubMed Google Scholar
33. Kreuz S, Siegmund D, Scheurich P, Wajant H . NF-κB upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001; 21: 3964–3973.
    Article CAS PubMed PubMed Central Google Scholar
34. Bernard D, Quatannens B, Vandenbunder B, Abbadie C . Rel/NF-κB transcription factors protect against tumor necrosis facor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J Biol Chem 2001; 276: 27322–27328.
    Article CAS PubMed Google Scholar
35. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim Kj, Ashkenazi A . Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611–620.
    Article CAS PubMed Google Scholar
36. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H . FADD/MORT 1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599–609.
    Article CAS PubMed Google Scholar
37. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I . Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000; 60: 4122–4129.
    CAS PubMed Google Scholar
38. Mitsiades N, Poulaki V, Mitsiades C, Tsokos M . Ewing’s sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and express DR4 and DR5 receptors. Cancer Res 2001; 61: 2704–2712.
    CAS PubMed Google Scholar
39. Secchiero P, Gonelli A, Celeghini C, Mirandola P, Guidotti L, Visani G, Capitani S, Zauli G . Activation of nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis inducing ligand-mediated cytoxicity on hematological malignancies. Blood 2001; 98: 2220–2228.
    Article CAS PubMed Google Scholar
40. Kaufmann SH, Earnshaw WC . Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42–49.
    Article CAS PubMed Google Scholar
41. Hengartner MO . The biochemistry of apoptosis. Nature 2000; 407: 770–776.
    Article CAS PubMed Google Scholar
42. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J . Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995; 270: 14255–14258.
    Article CAS PubMed Google Scholar
43. Olsson A, Diaz T, Aguilar-Santelises M, Osterborg A, Celsing F, Jondal M, Osorio LM . Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 2001; 15: 1868–1877.
    Article CAS PubMed Google Scholar
44. Bin L, Li X, Xu L-G, Shu H-B . The short splice form of Casper/cFLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett 2002; 510: 37–40.
    Article CAS PubMed Google Scholar
45. Yuan XJ, Whang YE . PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 2002; 21: 319–327.
    Article CAS PubMed Google Scholar
46. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM . Inhibition of nuclear factor κB attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91: 4624–4631.
    CAS PubMed Google Scholar

Download references